Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis

Figure 1 Immunohistochemical staining for heat shock protein 110 in gastric cancer patients. A: Representative images of gastric cancer. Representative images indicating the intensity of nuclear HSP110 staining (upper panel) and the percentage of nuclear-stained gastric cancer cells (lower panel) are shown. B: The three-year progression-free survival curve of 14 gastric cancer patients according to their nuclear HSP110 expression. HSP110: Heat shock protein 110.

Figure 2 Heat shock protein 110 suppression by KNK437 under hyperthermic conditions. HSP110 expression in MKN45 cells was suppressed by KNK437 under hyperthermic conditions of 43 °C. A: Western blots of HSP110 and β-actin expression; B: Relative expression of HSP110 (normalized to β-actin). C: Schematic representation of experimental timeline. HSP110: Heat shock protein 110; HT: Heat treatment.

Figure 3 Functional analysis of the MKN45 human gastric cancer cell line treated with KNK437 under hyperthermic conditions. A: Proliferation of MKN45 cells with and without KNK437-mediated HSP110 suppression. The results for normal (37 °C) (right panel) and hyperthermic (43 °C) (left panel) conditions are shown. Proliferation of MKN45 cells in the KNK437-mediated HSP110 suppression group (under hyperthermic condition) was significantly lower than that of the parental and control groups (^aP < 0.05); B: Cisplatin sensitivity in MKN45 cells in the presence or absence of KNK437-mediated HSP110 suppression. The results for normal (37 °C) (right panel) and hyperthermic (43 °C) (left panel) conditions are shown. Cisplatin sensitivity of MKN45 cells under the hyperthermic condition of 43 °C was significantly increased by KNK437-mediated HSP110 suppression (^aP < 0.05); C: Treatment of MKN45 cells with various therapeutic combinations. Therapeutic sensitivity of MKN45 cells treated with cisplatin and KNK437 under hyperthermic conditions was greater than that of cells with other therapeutic combinations (^aP < 0.05). HSP110: Heat shock protein 110; HT: Heat treatment.